Overview

High-dose Intravenous Vitamin C (HDIVC) as Adjuvant Therapy in Critical Patients With Positive COVID-19. A Pilot Randomized Controlled Dose-comparison Trial.

Status:
Not yet recruiting

Trial end date:
2022-05-15

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the impact of this HDIVC therapy in the first treatment of symptomatic Covid-19 patients in a time period of one week.

Phase:

Phase 3

Details

Lead Sponsor:

Hugo Galindo

Treatments:

Ascorbic Acid